Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP51A1 | Q16850 | 4/20 | 0.46 |
| ▸ | PYGL | P06737 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.41 |
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1401593 | 0.90 | F2 (0.50) | CYP51A1PYGLF2OPRD1 | |
| SCHEMBL3047893 | 0.87 | OPRD1 (0.49) | CYP51A1POLBALDH1A1MAPTHRH2 | |
| SCHEMBL27800005 | 0.87 | OPRD1 (0.49) | CYP51A1POLBALDH1A1MAPTHRH2 | |
| SCHEMBL24435894 | 0.85 | FPR2 (0.47) | ALDH1A1GAAHPGD | |
| SCHEMBL1401582 | 0.84 | F2 (0.48) | CYP51A1PYGLF2OPRD1 | |
| SCHEMBL1401268 | 0.81 | OPRD1 (0.48) | CYP51A1F2OPRD1 | |
| SCHEMBL1401188 | 0.81 | OPRD1 (0.44) | F2OPRD1 | |
| SCHEMBL868529 | 0.81 | CYP51A1 (0.38) | CYP51A1PYGLPOLBF2REN | |
| SCHEMBL2533450 | 0.81 | OPRD1 (0.36) | CYP51A1PYGLRENHRH2HRH1 | |
| SCHEMBL2533451 | 0.81 | OPRD1 (0.36) | CYP51A1PYGLRENHRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1789067-B8 | Use of growth hormone secretagogues for stimulating the motility of the gastrointestinal system | HELSINN HEALTHCARE SA (CH) | 2012-08-15 | — | — | EP | disclosed |
| EP-2146732-A1 | METHODS OF TREATING OR PREVENTING EMESIS USING GROWTH HORMONE SECRETAGOGUES | Helsinn Therapeutics (U.S.), Inc. (US) | 2010-01-27 | — | — | EP | disclosed |
| EP-2134341-A2 | METHOD OF TREATING CELL PROLIFERATIVE DISORDERS USING GROWTH HORMONE SECRETAGOGUES | Helsinn Therapeutics (U.S.), Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008124183-A1 | METHODS OF TREATING OR PREVENTING EMESIS USING GROWTH HORMONE SECRETAGOGUES | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008100448-A2 | METHOD OF TREATING CELL PROLIFERATIVE DISORDERS USING GROWTH HORMONE SECRETAGOGUES | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| EP-1789067-A2 | METHOD OF STIMULATING THE MOTILITY OF THE GASTROINTESTINAL SYSTEM USING GROWTH HORMONE SECRETAGOGUES | Sapphire Therapeutics, Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006020930-A2 | METHOD OF STIMULATING THE MOTILITY OF THE GASTROINTESTINAL SYSTEM USING GROWTH HORMONE SECRETAGOGUES | SAPPHIRE THERAPEUTICS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |